1.Expressions and correlation of Glil and β-catenin in the colorectal carcinoma
Hua REN ; Jianping ZHAO ; Yirui ZHAO
Cancer Research and Clinic 2013;(3):175-177
Objective To investigate the expression of Glil and β-catenin,which are central molecules of Hedgehog and Wnt signaling pathway,in colon cancer tissues and cell lines,and evaluate their relationship.Methods RT-PCR and Western blot were used to determine the expression of Glil and β-catenin in colon cancer tissues and cells.Interaction between endogenous Glil and endogenous 3-catenin was examined using immunoprecipitation method.Results Compared to corresponding normal tissues,the expression of Gli1 and β-catenin raised raising with one accord,the average growth rates were 42.69,72.11 respectively (P < 0.05).In colon cancer cell lines,the expression levels of Glil and β-catenin increased,which were 52.54,17.23,5.54 and 5.30,6.34,2.78 (all P < 0.05).Both of them were enhanced in three Wnt aberrant active cells visibly.The immunoprecipitation result indicated that there was an interaction between Glil and β-catenin in colon cancer cells.Conclusion The expression of Glil and β-catenin rise congruously in both colon cancer cells and tissues,and there is an interaction between them.This interaction between two key components of Hedgehog and Wnt signaling may suggest the possible crosstalk manner in these pathways.
2.Curative efficacy of euthyrox in treatment of hypothyroidism during pregnancy and its effect on levels of TSH,FT3 and FT4
Yirui HUANG ; Feng ZHAO ; Chengcheng YE
Chinese Journal of Biochemical Pharmaceutics 2017;37(3):270-272
Objective To study curative efficacy of euthyrox in treatment of hypothyroidism during pregnancy and its effect on levels of TSH , FT3 and FT4.Methods 100 patients of hypothyroidism during pregnancy who received therapy from June 2014 to June 2015 in our hospital were selected as research objects, and divited into control group and observation group,50 cases in each group.The control group was treated with Fugui Dihuang wan, while the observation group was treated with euthyrox on the basis of control group.Then the levels of TSH,FT3 and FT4, pregnancy outcome, neonatal adverse outcome, treatment outcome of two groups after treatment were compared.Results After treatment, the level of TSH in observation group was lower than the control group, the levels of FT3 and FT4 was higher than the control group ( P<0.05 ); Incidence of pregnancy complications in observation group was less than the control group [12.00%(6/50)vs 40.00%(20/40)](P<0.05);Total neonatal adverse outcomes [8.00%(4/50) vs 26.00%(13/50)](P<0.05); The total effective rate of observation group was statistically higher than that in the control group [96.00%(48/50) vs 80.00%(40/50)](P<0.05).Conclusion Euthyrox is well for hypothyroidism during pregnancy, which can improve TSH, FT3 and FT4 levels, relieve clinical symptoms.
3.Identification of the gene differentially expressed in female Anopheles anthropophagus and cloning of its full-length cDNA
Yonggang YE ; Yirui ZHAO ; Renli ZHANG ; Yijie GENG ; Dana HUANG ; Shitong GAO ; Ruiqing LIN ; Xingquan ZHU
Chinese Journal of Zoonoses 2009;(12):1177-1180,1185
To identify the gene differentially expressed in female Anopheles anthropophagus and to analyze its gene sequence, this gene amplified by PCR was identified by real-time PCR and its cDNA was then amplified with rapid amplification of cDNA ends (RACE) technology. It was found that the expression ratio of the female differentially expressed gene in female and male mosquitoes was 267.49 according to the formula F=2~(-⊿⊿CT).The size of mRNA of the gene was 364 bp, and the amino acid sequence deduced from the open reading frame (ORF) was found to be similar to the sequence of tectin protein of Culex quinquefasciatus and proteins of other species. The mRNA sequence of this gene was submitted to NCBI with a accession number of FJ907236. This gene may provide a foundation for further studies on the biological functions of mosquitoes.
4.Multicenter 5-year survival analysis of weekly Endostar combined with concurrent chemoradiotherapy for unresectable locally advanced non-small cell lung cancer
Honglian MA ; Fang PENG ; Yirui ZHAI ; Yong BAO ; Yujin XU ; Lujun ZHAO ; Dongming LI ; Zhouguang HUI ; Liming XU ; Xiao HU ; Lyuhua WANG ; Ming CHEN
Chinese Journal of Radiation Oncology 2021;30(1):23-28
Objective:To evaluate the 5-year survival outcome of patients with unresectable locally advanced non-small cell lung cancer (NSCLC) treated with Endostar in combination with platinum-based concurrent chemoradiotherapy.Methods:From March 2009 to June 2015, 115 patients with the unresectable locally advanced NSCLC from two prospective studies[Clinical trials 2009-2012(ClinicalTrials.gov NCT01894) and 2012-2015(ClinicalTrials.gov, NCT01733589)] were treated with Endostar in combination with platinum-based concurrent chemoradiotherapy. A total dose of 60-66 Gy was delivered in 30-33 fractions. Endostar was given 1 week prior to the beginning of radiotherapy, and repeated fortnightly during the concurrent chemoradiotherapy. After long-term follow up, survival outcome was evaluated in 104 patients treated with radiation dose of ≥60 Gy. Kaplan-Meier method was used for survival analysis. Univariate survival analysis was performed using the log-rank test.Results:Of 104 eligible patients, 60.6% of them had squamous carcinoma and 65.4% were classified in stage Ⅲ B. All the patients received ≥2 cycles of Endostar and 93.3% of them received 4 cycles of Endostar. The median follow-up time was 68.3 months. The median overall survival (OS) and median progression-free survival (PFS) were 31.3 and 13.9 months, respectively. The 3-year and 5-year OS were 45.6% and 35.7%, respectively. The 3-year and 5-year PFS were 27.1% and 24.9%, respectively. Univariate analysis indicated that sex, ECOG, pathological type, clinical stage, radiotherapy technique, chemotherapy regimen, chemotherapy cycle and cycle of Endostar use were not associated with OS. Late radiation injury occurred in 14.4% of patients, and no grade 4-5 late injury was observed. Conclusion:Patients with unresectable locally advanced NSCLC treated with Endostar fortnightly in combination with platinum-based concurrent chemoradiotherapy achieve better OS than historical data with tolerable toxicities.
5.Clinical guideline for diagnosis and treatment of adult ankylosing spondylitis combined with thoracolumbar fracture (version 2023)
Jianan ZHANG ; Bohua CHEN ; Tongwei CHU ; Yirui CHEN ; Jian DONG ; Haoyu FENG ; Shunwu FAN ; Shiqing FENG ; Yanzheng GAO ; Zhong GUAN ; Yong HAI ; Lijun HE ; Yuan HE ; Dianming JIANG ; Jianyuan JIANG ; Bin LIN ; Bin LIU ; Baoge LIU ; Dechun LI ; Fang LI ; Feng LI ; Guohua LYU ; Li LI ; Qi LIAO ; Weishi LI ; Xiaoguang LIU ; Yong LIU ; Zhongjun LIU ; Shibao LU ; Wei MEI ; Yong QIU ; Limin RONG ; Yong SHEN ; Huiyong SHEN ; Jun SHU ; Yueming SONG ; Honghui SUN ; Tiansheng SUN ; Yan WANG ; Zhe WANG ; Zheng WANG ; Yongming XI ; Hong XIA ; Jinglong YAN ; Liang YAN ; Wen YUAN ; Gang ZHAO ; Jie ZHAO ; Jianguo ZHANG ; Xiaozhong ZHOU ; Yue ZHU ; Yingze ZHANG ; Dingjun HAO ; Baorong HE
Chinese Journal of Trauma 2023;39(3):204-213
Ankylosing spondylitis (AS) combined with spinal fractures with thoracic and lumbar fracture as the most common type shows characteristics of unstable fracture, high incidence of nerve injury, high mortality and high disability rate. The diagnosis may be missed because it is mostly caused by low-energy injury, when spinal rigidity and osteoporosis have a great impact on the accuracy of imaging examination. At the same time, the treatment choices are controversial, with no relevant specifications. Non-operative treatments can easily lead to bone nonunion, pseudoarthrosis and delayed nerve injury, while surgeries may be failed due to internal fixation failure. At present, there are no evidence-based guidelines for the diagnosis and treatment of AS combined with thoracic and lumbar fracture. In this context, the Spinal Trauma Academic Group of Orthopedics Branch of Chinese Medical Doctor Association organized experts to formulate the Clinical guideline for the diagnosis and treatment of adult ankylosing spondylitis combined with thoracolumbar fracture ( version 2023) by following the principles of evidence-based medicine and systematically review related literatures. Ten recommendations on the diagnosis, imaging evaluation, classification and treatment of AS combined with thoracic and lumbar fracture were put forward, aiming to standardize the clinical diagnosis and treatment of such disorder.
6.Analysis of Influential Factors of Tacrolimus Blood Concentration in 104 Patients with Nephrotic Syndrome of Different Nationalities
Lili ZHU ; Yirui WANG ; Gang HAN ; Bosong CHEN ; Yuan YUAN ; Guoru CHEN ; Abudureyimu GULIMIRE ; Jun ZHAO
China Pharmacy 2019;30(15):2110-2114
OBJECTIVE: To investigate the influential factors of tacrolimus (TAC) blood concentration in patients with nephrotic syndrome (NS) of different nationalities. METHODS: In retrospective study, clinical information of 104 patients who diagnosed as NS and met inclusion/exclusion criteria were collected from the First Affiliated Hospital of Xinjiang Medical University during Dec. 2017 and Nov. 2018, including gender, age, ethnicity, height, body weight, laboratory test items, combined drug use and TAC dosage. Influential factors for TAC blood concentration were analyzed by SPSS 22.0 software, and effects of combined use of Wuzhi capsule on steady-state blood trough concentration ([ss][c min]) and dose of TAC were also analyzed. RESULTS: Among 104 patients, totally TAC blood concentration of 394 case times were monitored; using TAC standardized blood concentration as endpoint, Han nationality group was significantly lower than Uygur and Kazak nationality group (P=0.003); patients receiving combined use of Wuzhi capsule were significantly higher than those without combined use of Wuzhi capsule (P=0.056); the patients with combined use of calcium antagonists was significantly higher than the patients without calcium antagonists (P=0.01); the patients with combined use of proton pump inhibitors were significantly lower than those without combined proton pump inhibitors (P=0.01); patients with normal hematocrit were significantly lower than those with abnormal hematocrit (P=0.001); patients with normal urea nitrogen were significantly lower than those with abnormal urea nitrogen (P<0.001). The dose of TAC in patients receiving combined Wuzhi capsule were significantly lower than those without combined use of Wuzhi capsule (P=0.001), there was no significant difference in [ss][c min] of TAC between them (P=0.29). CONCLUSIONS: For NS patients, the effects of ethnicity, calcium antagonists, proton pump inhibitors, hematocrit, urea nitrogen and Wuzhi capsules on TAC blood concentration should be considered when TAC is used.